This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): formoterol fumarate
Description: Foradil (Formoterol fumarate) is a long-acting (12 hours) selective beta2-adrenergic receptor agonist with a rapid onset of action (3 minutes). It is dosed twice a day. Inhaled Foradil acts locally in the lung to promote bronchodilation. Foradil Aerolizer is a single dose dry powder inhaler. A metered-dose inhaler is available in some countries.
Deal Structure: On 11/1/02, Schering-Plough and Novartis an affiliate of Novartis AG announced an agreement giving Schering-Plough exclusive U.S. distribution and marketing rights to Novartis' FORADIL AEROLIZER (formoterol fumarate inhalation powder), a selective, long-acting beta2-agonist indicated for the maintenancetreatment of asthma and chronic obstructive pulmonary disease (COPD), and theacute prevention of exercise-induced bronchospasm.
Under terms of the agreement, Novartis receives an upfront license payment and could receive additional payments upon the achievement of certain milestones. In addition, Schering-Plough will pay a royalty on its net salesof FORADIL AEROLIZER. Specific financial terms of the agreement are not beingdisclosed.
Formoterol is licensed by Novartis from Yamanouchi Pharmaceuticals (now Astellas Pharma).
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which...See full deal structure in Biomedtracker
Partners: Novartis AG Astellas Pharma, Inc.
Foradil Aerolizer News
Pink Sheet Novartis Foradil Aerolizer
Additional information available to subscribers only: